Managing advanced melanoma has evolved dramatically with the approval of immune checkpoint inhibitors. However, clinicians still lack robust predictive biomarkers to tailor first-line regimens. In clinical practice, evaluating LAG3 expression in melanoma offers valuable insights into the tumor-immune microenvironment. By distinguishing immune-infiltrated tumors from immune-desert phenotypes, transcriptional profiling helps oncologists match individual patients with the most appropriate immunotherapy strategy. Consequently, understanding these biomarkers is essential for optimizing survival outcomes while minimizing treatment-related toxicity.

Biological Significance of LAG3 Expression in Melanoma

Lymphocyte activation gene-3 (LAG-3) functions as a crucial immune checkpoint receptor expressed primarily on activated CD8+ T cells, regulatory T cells, and natural killer cells. When LAG-3 binds major histocompatibility complex class II, it delivers inhibitory signals that dampen T-cell proliferation and cytokine secretion. Therefore, high expression of LAG-3 signifies sustained antigenic stimulation and adaptive immune resistance within the tumor bed. Historically, investigators focused predominantly on programmed death-ligand 1 (PD-L1) expression when assessing tumor immunogenicity. Nevertheless, PD-L1 immunohistochemistry provides only a partial picture of the complex microenvironment. Recent multi-omic studies demonstrate that measuring RNA transcript levels of LAG-3 uncovers vital biological nuances. Tumors exhibiting elevated LAG-3 transcripts frequently harbor rich immune infiltrates that have mounted an antitumor response. Consequently, elevated LAG-3 expression does not simply represent immune suppression. Instead, it serves as a hallmark of an inflamed tumor microenvironment poised for reactivation. In contrast, tumors lacking LAG-3 expression often represent immunologically quiescent or excluded niches. Recognizing these biological patterns allows clinicians to evaluate host-tumor interactions accurately and anticipate therapeutic responsiveness.

Differential Clinical Outcomes Across Immunotherapy Regimens

Recent real-world data from comprehensive clinical cohorts reveal striking differences in patient outcomes based on biomarker status. Specifically, among patients receiving first-line anti-PD-1 monotherapy, high LAG-3 expression correlated with remarkable therapeutic responses. Patients in the LAG-3-high cohort achieved an objective response rate of sixty-seven percent, compared to only fifteen percent in the LAG-3-low cohort. Furthermore, multivariable analyses demonstrated a substantial reduction in the risk of death for high expressors receiving monotherapy. In contrast, patients receiving dual checkpoint inhibition with anti-CTLA-4 and anti-PD-1 exhibited comparable response rates regardless of their baseline LAG-3 status. The objective response rate reached forty-six percent in LAG-3-high patients and thirty-seven percent in LAG-3-low patients, showing no statistically significant divergence. Consequently, these findings highlight a meaningful treatment-biomarker interaction in advanced melanoma management. While single-agent anti-PD-1 therapy effectively reactivates pre-existing, inflamed immune microenvironments, it demonstrates limited efficacy in immune-cold tumors. Dual blockade, however, appears capable of overcoming this immunological inertia. Thus, evaluating transcript levels prior to therapy initiation provides actionable predictive information.

Correlation with the Tumor Immune Microenvironment

To understand why treatment outcomes diverge so dramatically, researchers analyzed the multi-omic architecture of advanced melanoma specimens. Notably, high LAG-3 expression correlates strongly with CD274 expression, the gene encoding PD-L1. More than half of LAG-3-high tumors demonstrated PD-L1 positivity, whereas only a tiny fraction of LAG-3-low tumors exhibited detectable PD-L1. Additionally, bioinformatic deconvolution revealed that LAG-3-high tumors harbor significantly higher proportions of adaptive immune cells, including CD8+ cytotoxic T lymphocytes and memory B cells. These tumors also contain higher concentrations of regulatory T cells, which naturally accumulate in inflamed tissue sites. Conversely, LAG-3-low specimens consistently displayed features of an immune desert, lacking essential effector cells. Furthermore, researchers evaluated tumor mutation burden and neoantigen loads across both groups. Interestingly, while genomic alterations create neoantigens, the actual immune infiltration pattern dictated clinical sensitivity to single-agent checkpoint blockade. Therefore, high LAG-3 expression serves as a dependable surrogate for a pre-existing antitumor immune infiltrate. By capturing this active immune equilibrium, RNA sequencing provides a reliable reflection of the host-tumor dynamic.

Practical Considerations for Clinical Decision-Making

Selecting an optimal first-line regimen represents one of the most critical challenges in melanoma oncology. Currently, oncologists must frequently choose between anti-PD-1 monotherapy, dual CTLA-4/PD-1 inhibition, or novel anti-LAG-3 combinations. Although dual checkpoint blockade offers durable disease control, it causes severe immune-related adverse events in over half of treated individuals. Consequently, identifying patients who can safely achieve long-term survival with single-agent therapy remains an urgent clinical priority. Real-world transcriptomic data suggest that patients with high LAG-3 expression achieve robust disease control with anti-PD-1 monotherapy alone. For these individuals, single-agent therapy provides excellent response rates while sparing them the considerable toxicities of dual blockade. On the other hand, patients with LAG-3-low tumors face poor outcomes with monotherapy. Therefore, clinicians should strongly consider dual checkpoint inhibition or clinical trial enrollment for this specific subset. Moreover, multidisciplinary tumor boards can leverage comprehensive transcriptomic profiling to guide complex clinical choices. Balancing efficacy against toxicity through precise biomarker stratification ultimately ensures safer and more personalized patient care.

Translating Transcriptomic Biomarkers into Oncology Practice

Implementing transcriptomic profiling in routine clinical workflows offers enormous promise for precision immuno-oncology. Historically, pathologists relied solely on immunohistochemistry to assess individual proteins on tissue sections. However, immunohistochemistry often suffers from inter-observer variability, heterogeneous staining, and inconsistent scoring cutoffs across clinical platforms. In contrast, comprehensive next-generation RNA sequencing provides standardized, objective, and reproducible quantitation of multiple immune checkpoint transcripts simultaneously. Furthermore, RNA assays evaluate entire gene networks, providing quantitative estimates of immune cell infiltration and microenvironment polarization. Despite these technical strengths, clinicians must address practical challenges before widespread adoption occurs. Genomic and transcriptomic sequencing requires adequate tissue acquisition, specialized laboratory infrastructure, and turnaround times of several days. Additionally, healthcare institutions must evaluate cost-effectiveness and accessibility, particularly in resource-constrained oncology settings. As molecular diagnostic platforms become increasingly integrated into tertiary cancer centers, RNA-based biomarker testing will likely become routine. Thus, oncologists who familiarize themselves with transcriptomic signatures today will lead the transition toward personalized checkpoint immunotherapy tomorrow.

Frequently Asked Questions

How does LAG-3 expression influence response to anti-PD-1 monotherapy in melanoma?

High LAG-3 expression indicates an inflamed tumor microenvironment enriched with functional CD8+ cytotoxic T cells and adaptive immune components. Consequently, patients with high LAG-3 transcript levels achieve markedly superior objective response rates and longer overall survival under single-agent anti-PD-1 therapy. In contrast, tumors with low LAG-3 levels represent immune-desert environments that show minimal response to monotherapy, highlighting LAG-3 as a strong predictive biomarker for treatment stratification.

Can dual CTLA-4 and PD-1 blockade overcome low baseline LAG-3 expression?

Yes, clinical evidence indicates that dual checkpoint inhibition with anti-CTLA-4 and anti-PD-1 achieves comparable response rates in both LAG-3-high and LAG-3-low cohorts. While monotherapy falters in immunologically cold tumors, CTLA-4 blockade promotes T-cell priming in lymphoid organs and enhances effector cell trafficking into the tumor. Therefore, dual checkpoint inhibition can overcome the immunological inertia typical of LAG-3-low melanoma, providing meaningful clinical benefit despite an uninflamed baseline microenvironment.

Why is RNA sequencing advantageous compared to immunohistochemistry for LAG-3 assessment?

RNA sequencing provides an objective, standardized, and highly reproducible measurement of LAG-3 transcript abundance across tumor tissue. Unlike immunohistochemistry, which frequently suffers from antibody variability, subjective visual scoring, and patchiness, transcriptomic assays quantify multiple immune checkpoints simultaneously. Furthermore, RNA profiling enables computational deconvolution of the tumor microenvironment, revealing CD8+ T-cell infiltration, regulatory T cells, and co-expressed biomarkers that collectively provide a comprehensive view of tumor immunogenicity.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Mehmi I et al. Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection. Oncologist. 2026 Nov 12. doi: undefined. PMID: 43016358.

Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine. 2022;386(1):24-34.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma. New England Journal of Medicine. 2022;386(24):2303-2314.